Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18227898 | 1.00 | HTR7 (0.60) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL9742163 | 0.78 | GRM2 (0.61) | HTR7 | |
| SCHEMBL16142256 | 0.78 | HTR7 (0.59) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL22672949 | 0.78 | HTR7 (0.62) | HTR7DRD3DRD4DRD2HTR1A | |
| SCHEMBL9742158 | 0.77 | HTR7 (0.59) | HTR7DRD3DRD4KCNH2SIGMAR1 | |
| SCHEMBL9741903 | 0.77 | HTR7 (0.62) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL9741906 | 0.77 | HTR7 (0.62) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL9741902 | 0.77 | HTR7 (0.62) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL18227877 | 0.76 | HTR7 (0.61) | HTR7DRD3DRD4KCNH2DRD2 | |
| SCHEMBL18236143 | 0.75 | HTR7 (1.00) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | claimed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | claimed |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | HTR7 83/4885DRD3 510/4885DRD4 593/4885 |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | HTR7 68/4885DRD3 613/4885DRD4 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.